SCYNEXIS INC Form 8-K Summary
Business Context and Reporting Period
SCYNEXIS, Inc. (SCYX) filed this Current Report on Form 8-K on May 13, 2021. The filing discloses the entry into a material definitive agreement and the creation of a direct financial obligation. The company is a biopharmaceutical firm focused on the development of ibrexafungerp.
Key Financial Metrics and Debt Structure
The company secured a Term Loan facility with an aggregate principal amount of up to $60.0 million from Hercules Capital, Inc. and Silicon Valley Bank. The filing does not provide current revenue, profit, or cash flow figures, as this is a transactional report rather than a periodic financial statement.
- Total Facility Size: Up to $60.0 million.
- Initial Funding: $20.0 million received at closing.
- Interest Rate: Variable, equal to the greater of 9.05% or the Prime Rate plus 5.80%.
- Maturity Date: March 3, 2025 (automatically extendable to May 1, 2025 under certain conditions).
- Repayment Terms: Interest-only payments permitted through November 1, 2023, potentially extendable to May 1, 2024 or further upon milestone achievement. Principal repayment begins after the interest-only period in equal monthly installments.
Material Changes and Loan Tranches
The $60.0 million facility is structured in four tranches contingent on specific milestones and timeframes:
- Tranche 1: $20.0 million (Received at closing).
- Tranche 2: Up to $10.0 million available upon FDA approval of ibrexafungerp for vaginal yeast infections (First Performance Milestone), accessible between June 1, 2021, and June 30, 2022.
- Tranche 3: $5.0 million available upon achieving the First Performance Milestone and meeting primary endpoints in the Phase 3 CANDLE study, accessible between September 30, 2021, and June 30, 2022.
- Tranche 4: Up to $25.0 million available in $5.0 million increments between January 1, 2022, and December 31, 2023, subject to the First Performance Milestone and a financial covenant regarding the ratio of outstanding loan principal to net product revenues.
Guidance, Risks, and Covenants
The Loan Agreement includes a financial covenant requiring the maintenance of specific trailing three-month net product revenue levels from ibrexafungerp sales, commencing June 30, 2022. This covenant may be waived if the company maintains unrestricted cash at Silicon Valley Bank equal to at least 50% of the total outstanding Term Loan principal.
Collateral and Equity: The loan is secured by a first-priority security interest on substantially all personal property, excluding intellectual property. In connection with the loan, the company issued warrants to the lenders to purchase common stock. The total shares purchasable under the warrants will not exceed 0.04 multiplied by the aggregate loan advances, divided by the exercise price.
Investor Verification Checklist
- Verify the exact exercise price of the warrants issued to Hercules and SVB, as the filing text does not specify this value.
- Monitor the status of the FDA approval for ibrexafungerp (First Performance Milestone) to determine eligibility for Tranches 2, 3, and 4.
- Review the Phase 3 CANDLE study results for the primary endpoint and safety profile required for Tranche 3.
- Assess the company's ability to meet the financial covenant regarding the ratio of debt to net product revenues starting June 30, 2022.
- Confirm the specific terms of the automatic maturity extension to May 1, 2025.